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LUNASIN REDUCES THE MELANOMA STEM CELL POPULATION IN 
VITRO AND INHIBITS TUMOR PROLIFERATION IN VIVO 
Christopher P. Shidal 
October 30, 2014 
Lunasin is a 44 amino acid peptide derived from the soybean seed that has been shown to 
have cancer chemopreventive and chemotherapeutic properties. In this study, we 
investigated the potential utility of lunasin as a chemotherapeutic in a melanoma model.  
Initial studies showed that lunasin has little activity against established melanoma cell 
lines in vitro using adherent culture methods; however, lunasin’s in vitro activity was 
significantly higher in non-adherent colony-forming assays in soft agar and oncosphere 
assays. These results led us to investigate whether lunasin selectively affects cancer 
initiating cells (CIC) that are known to be present in these melanoma cell lines. We found 
that lunasin treatment did selectively inhibit the proliferation of high-ALDH-expressing 
malignant melanoma initiating cells (MMIC) in vitro, and had the striking effect of 
preventing oncosphere formation under non-adherent culture conditions. These in vitro 
results were extended into mouse xenograft studies using both bulk melanoma cells and 
isolated CICs.  Lunasin significantly inhibited tumor growth in both cases, with the 
highest inhibition being observed in tumors initiated by MMICs.   Mechanistic studies 
suggested that lunasin inhibits CIC proliferation in vitro through interactions with 
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integrins and disruption of integrin signaling by inhibiting the activity of integrin binding 
partners such as integrin-linked kinase (ILK) and focal adhesion kinase (FAK).  These  
studies demonstrate for the first time that lunasin has activity against putative CICs and 
that lunasin may have utility as a therapeutic agent for the treatment of melanoma. 
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Lunasin as an Anticancer Agent 
Lunasin is a soy derived peptide that has demonstrated anticancer, anti-
inflammatory, antioxidant, and immunomodulatory activity [1-4].  Lunasin has been 
reported as a 43 amino acid fragment present in processed 2S albumin protein [5]; 
however, we recently identified a native 44 amino acid sequence of lunasin isolated from 
defatted soy flour consisting of the sequence: 
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDDN [6].  Lunasin 
has been proposed to have three distinct domains that are responsible for its therapeutic 
and chemopreventive activity: an RGD sequence involved in internalization of the 
peptide via integrin binding, a poly-aspartic acid tail that binds lysine residues present in 
H3 and H4 histone tails, and a hypothesized chromatin binding domain [7, 8].  Limited 
studies describe the direct chemotherapeutic effects of lunasin against cancer as it is 
generally defined as a chemopreventive agent based on earlier studies by de Lumen and 
coworkers [7, 9-12].  Thus, many questions remain about the number of cancer types 
sensitive to lunasin, the possible mechanisms of lunasin’s anticancer effects, and to what 
extent lunasin is involved with the tight correlation of soy consumption with a protective 
effect against certain cancer types [13-15]. 
Lunasin has been found to inhibit transformation induced by multiple carcinogens 
and viral oncogenes [7, 9, 16-18].  Moreover, studies in our lab indicate lunasin is able to 
inhibit transformation of mouse fibroblast cells induced by carcinogens present in 
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cigarette smoke including cadmium and nicotine-derived nitrosamine ketones (data not 
shown).  The most discussed mechanism of action of lunasin is the inhibition of histone 
acetyltransferases (HATs) and modulation of histone acetylation.   
The acetylation of core histones initiates the unwinding of tightly packed DNA 
from the nucleasome complex allowing for transcription of target genes (Figure 1).  HAT 
inhibition alters normal acetylation patterns leading to hypoacetylation of histone tails, 
repressing transcription and can account for global cellular effects including proliferation, 
cell cycling, and apoptosis [19-21].    Although some evidence supports HAT inhibition 
as lunasin’s primary mechanism of action, to date, there have been no functional studies 
to support this hypothesis.  Moreover, as new principal mechanisms of lunasin action are 
still being discovered, it is not clear in the different experimental systems that have been 
studied whether histone acetylation is involved in all cases.    
 Studies in our lab confirm a significant antiproliferative effect of lunasin on non-
small cell lung cancer (NSCLC), an effect which is mediated by disrupting cell cycle 
signaling (McConnell, 2014).  Previous studies have acknowledged that lunasin reduces 
cyclin-dependent kinase (CDK) levels, and may accommodate aspirin-induced apoptosis 
in breast cancer models [22, 23].  Additionally, lunasin was reported to induce apoptosis 
and alter expression of matrix adhesion proteins in metastatic colon cancer [24].  Lunasin 
was recently shown to suppress FAK/ERK/NF-κB signaling in human colon cancer as 
well as potentiate the antiproliferative and antimetastatic effects of oxaliplatin [25].  
 Sadly, many plant-derived compounds (e.g. curcumin) are quickly metabolized 
or excreted resulting in poor bioavailability, however, lunasin is active and bioavailable 
in humans consuming physiologically relevant amounts of soy [26].  In this study, 
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volunteers were orally dosed with lunasin (155.5 mg/day) in 50 grams (g) soy protein for 
5 consecutive days.  De Mejia et al. revealed lunasin is orally bioavailable; however, 
incomplete GI absorption resulted in a low concentration (71.0 ng/mL or 
approximately14 μM) lunasin in plasma samples [26].  
  Prior studies suggest that lunasin interacts with a specific subset of integrin 
subunits, as supported by a 2012 study by De Meija and coworkers [2].  Furthermore, 
recent studies suggest that internalization of lunasin is mediated by αvβ3 integrins via 
clathrin and caveolin-mediated endocytosis [27].  Proximity ligation assays (PLA) verify 
that the specific integrin subunits αv, α5, β1 and β3 network with the lunasin peptide 
(Inaba and Davis, unpublished data).  In normal cells, integrins mediate cell-cell and cell-
matrix adhesions by recognizing binding motifs (i.e. RGD) as well as cooperating with 
growth factor receptors to induce proliferative and survival signaling [28, 29].  The 
ubiquitous nature of integrin signaling provides an interesting target for cancer 
prevention and treatment because many of these pathways are deregulated in cancer and 
result in uncontrolled proliferation and metastasis.  More specifically, we are interested in 
elucidating the effects of lunasin treatment on downstream pathways associated with 




Integrins as a targeted therapy in melanoma patients 
Integrins are vital to most cellular processes, and remain an important and 
underexplored target for cancer therapies.  Recent studies utilizing RGD peptides have 
shown targeting of integrins as a viable treatment alternative in melanoma therapy by 
inhibiting tumor angiogenesis, growth, and metastasis [30-32].  Integrins are 
heterodimeric membrane proteins primarily implicated in cell adhesion and migration 
[33, 34]; yet, integrins have also been reported to be intimately involved in cell growth, 
differentiation, and survival [35, 36].  Two families consisting of 18 α-subunits and 8 β-
subunits comprise the 24 heterodimeric proteins known in humans [37], combined with 
complex conformational states and overlapping ligand specificities, make integrin 
signaling flexible yet highly intricate [38].  Furthermore, integrin expression profiles are 
largely dependent upon two dimensional (i.e. adherent conditions) adhesion versus three 
dimensional (i.e. non-adherent) adhesion [39], and can result in recruitment of very 
different subsets of proteins.  Proteins attracted to different adhesion structures (e.g. 
paxillin) can produce diverse yet specific signaling cascades.   
By categorizing NSCLC lines based on integrin expression profiles, we associated 
explicit integrin subunits with lunasin sensitivity (McConnell and Davis, unpublished 
data).  Moreover, we showed lunasin exerts its anticancer effects in NSCLC by reducing 
activating phosphorylations of v-akt murine thymoma viral oncogene homolog 1 (AKT), 
Focal adhesion kinase (FAK), and interactions of β-subunits with integrin-linked kinase 
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(ILK), thereby altering signaling pathways downstream of integrin-ligand binding 
(unpublished data).   
In melanoma models, the integrin αvβ3 is currently the predominant target for 
therapeutic applications of integrin antagonists.  Integrin αvβ3 is expressed at low levels 
in non-transformed epithelial cells relative to melanoma cells [40], as αvβ3 expression 
has been related to metastatic potential and dissemination of melanoma neoplasms to a 
metastatic phenotype [41, 42].  Crosstalk between integrins and growth factor receptors 
has been well documented [43, 44].  Enhanced cancer cell survival has been attributed to 
a number of interactions between integrin signaling and other pathways including 
increased BCL-2 expression, PI3K-AKT activation, or NF-κB signaling [45-47].  We 
predict that lunasin binds αvβ3 integrins through its RGD domain and inhibits 
proproliferative and prosurvival signaling.   
Certain integrins have specific roles in melanoma;  for instance, it has been shown 
that α4β1, a homing molecule on leukocytes that binds VCAM-1, is absent on 
melanoctyes, yet present in melanoma cultures [48].  Consequently, α4β1 may help 
melanomas mimic hematopoietic cells by enabling melanoma migration into tissues that 
express sing VCAM-1 [49].  Other integrins implicated in melanoma are α3β1 and α5β1, 
which were elevated in metastatic melanoma tissue.  Furthermore, α1β1, α2β1 and α6β1 
integrin subunits were found to be reduced in metastatic versus primary melanoma [48]. 
Roles of integrins in CICs are somewhat ambiguous.  Recent studies show that 
integrin subunits may be a viable marker for CICs and are responsible for stem cell pool 
maintenance and differentiation mediated by FAK [50, 51].  CICs are proposed to be 
more tumorigenic based on properties such as chemoresistance, immune evasion, and 
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self-renewal capabilities [52, 53].  Cilengitide (Merck Co.), a cyclic RGD (cRGD) 
peptide, has been used to treat glioblastoma and is the first integrin inhibitor to be used in 
Phase III clinical trials [54].  By selectively targeting melanoma stem cells and altering 
integrin signaling, we may provide a novel treatment for malignant metastatic melanoma.  
Furthermore, targeting of integrin subunits explicitly expressed on cancer cells may 




Melanoma and the presence of melanoma stem cells 
Skin cancers account for nearly half of all diagnosed cancer cases in the United 
States and have increased in frequency over the last thirty years [55].  Melanoma is 
estimated to account for 76,000 new cancer cases in 2014 [56].  Despite being less 
frequent than other skin cancers, nearly 75% of skin cancer deaths are attributed to 
melanoma [56].  Even more unnerving, NCI’s Surveillance, Epidemiology, and End 
Results (SEER) program estimates cases of melanoma have nearly tripled in the past 
thirty years increasing from 7.9 (per 100,000) in 1975 to 22.7 in 2011, while 5-year 
survival rates remain constant.  Early detection and diagnosis is paramount for overall 
survival with 5-year survival rates of 98%, 62%, and 16% for localized, regional, and 
distant diseases, respectively [56].  Continued research of melanoma has provided several 
“cracks in the armor” of metastatic melanoma leading to the development of several 
targeted therapies that aim to inhibit proliferation, metastasis, and angiogenesis of 
primary and secondary tumors.  One such targeted therapy is vemurafenib, which 
decreases melanoma cell viability and proliferation resulting in tumor regression and 
increasing overall mean survival time [57, 58]. 
Vemurafenib targets a mutated form of the B-Raf protein found in approximately 
60% of melanomas in which a V600E substitution leads to constitutive Raf signaling 
within the mitogen-activated protein kinase (MAPK) cascade [59].  In the majority of 
patients harboring this mutation, mean survival time has been improved with 
vemurafenib; however, after initial tumor regression, many patients experience 
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recurrence of tumors that are vemurafenib-resistant [60-62].   Conferred resistance to 
vemurafenib may occur through a number of mechanisms including, but not limited to, 
feedback activation of epithelial growth factor receptor (EGFR), upregulation of other 
Raf proteins, or upregulation of N-Ras [62-64].  Our present studies focus on developing 
lunasin as an adjuvant therapy to targeted therapies such as vemurafenib.  We found that 
lunasin interacts additively with vemurafenib to reduce the ability of melanoma cells to 
proliferate and form oncospheres in vitro, and may sensitize cell lines with acquired 
resistance to subsequent vemurafenib treatments via inhibition of PI3K/AKT signaling 
(data not shown). 
One explanation for the reformation of palpable tumors with chemoresistance is 
the presence of CICs within the bulk tumor population.  The presence of CICs and their 
origin have become a topic of debate [65-69].  According to the cancer stem cell (CSC) 
theory, a subset of cells within the tumor population have properties that resemble 
physiological stem cells including the ability to self-renew while also giving rise to 
daughter cells that differentiate to reform heterogeneous tumor populations [65].  In this 
study, we will show that CICs exist within bulk tumor populations at a relatively high 
rate, and that this subset of cells displays enhanced tumorigenicity.   
Discovery of melanoma cells with stem-like plasticity was initially found in 
patient tumors overexpressing CD20 and CD133 [70, 71].  CD20 is a membrane-
spanning surface molecule generally found on B lymphocytes; per se, it is the molecular 
target for monoclonal antibodies (e.g. rituximab) for treatment of select leukemias and 
lymphomas.  CD133 (also called prominin-1) is a novel, membrane-spanning protein of 
no known function that is classified as a marker for primitive hematopoietic and neural 
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stem cells.  These subsets of cells were found to have properties of stem cells as well as 
enhanced ability to form palpable tumors in immunodeficient mice.  Ensuing studies 
verify ATP-binding cassette sub-family B member 5 (ABCB5), a drug transporter 
playing a key role in chemoresistance, and Low-Affinity Nerve Growth Factor Receptor  
(LNGFR/CD271),  a member of the tumor necrosis factor (TNF) receptor family 
involved in survival and differentiation of neurons, as viable MMIC biomarkers [53, 72]. 
However, scientists are slow to embrace this concept for a number of valid reasons.  One 
concern remains the standardization of techniques for identifying and propagating cancer 
stem cells.  Serial dilution and transplantation of CICs into NOD/SCID mice has long 
been the gold standard for determining stem cell populations; however, spheroid assays 
in addition to genetic lineage tracing provide in vitro assays for CIC classification [66].   
To make matters more complicated, some evidence supports plasticity of 
differentiated cancer cells in a breast cancer model [73].  By reverting to a 
dedifferentiated phenotype, stem-like cells arise de novo in response to environmental 
cues [73].   These data support the theory of bidirectional movement between stem and 
non-stem compartments, and have serious implications on the plasticity of cells in cancer 
models as well as subsequent therapeutic strategies.   
Although populations of stem-like cells are recognized in melanoma cell lines, the 
frequency of these cells is highly variable, ranging from less than 1% up to nearly 25% 
[53, 74].  The incidence of cancer stem cells seems dependent upon the in vivo model, the 
biomarker used for identification, and the tumor microenvironment [49, 75].  Conflicting 
reports indicate that tumor samples enriched for MMIC markers have enhanced tumor 
forming capacity.  Quintana [74] showed tumorigenic cells are phenotypically 
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heterogeneous in melanomas, as significant in vivo tumor growth was marginal based on 
select CSC biomarkers.  Despite these findings, numerous studies report superior tumor 
forming capabilities of cells enriched for melanoma stem cell biomarkers including 
ABCB5 [76], CD133 [71], CD271 [72], and ALDH [77].   
 Aldehyde dehydrogenase (ALDH) is a family of detoxifying enzymes responsible 
for metabolism of certain alkylating agents such as cyclophosphamide.  Enrichment for 
melanoma intiating cells by intracellular ALDH staining has come with mixed reviews; 
however, most evidence supports ALDH as a MMIC biomarker [77-80].  ALDH 
expression has also successfully been used to detect CICs in breast and colon cancer 
models [81, 82].   In this study, we implement a commercially available ALDH detection 
kit to identify and sort melanoma cells expressing elevated levels of ALDH from ALDH 
negative fractions.   
Unfortunately, current therapeutics heavily rely on efficacy against bulk tumor 
cells and the ability of the drug to reduce primary or secondary tumor size. We suggest 
that lunasin specifically targets MMICs and reduces this aggressive subpopulation of 
cells.  We are currently elucidating mechanisms for this effect, but believe lunasin 
treatment may induce terminal differentiation of cancer stem cells, inhibit self-renewal 
capacity, or alter integrin signaling leading to antiproliferative effects.  By reducing CIC 
populations, we hypothesize lunasin alters the ability of melanoma tumor cells to 
establish palpable tumors in vivo.  By selectively reducing the population of melanoma 





Lunasin Isolation and Purification 
Lunasin was isolated from “white flake,” a product resulting from the flaking and 
defatting of soybeans via hexane extraction.  The extraction and purification was scaled 
and performed by Kentucky BioProcessing (KBP) as previously described [6].  Briefly, 
lunasin was extracted from defatted soy flour and purified using a combination of Q-
Sepharose FF chromatography, ultrafiltration utilizing a 30 kDa membrane, and. reverse-
phase chromatography.  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) analysis indicate these lunasin preparations have >99% purity. 
Cell Culture and Reagents 
SKMEL-28 and A375 cell lines were obtained from American Type Culture 
Collection (ATCC, Rockville, MD, USA).  Cell lines were grown in Dulbeccos Modified 
Eagles Medium (DMEM) and supplemented with 10% fetal bovine serum (FBS), 100 
U/mL penicillin, and 100 μg/mL streptomycin.  Cells were incubated at 37˚C at 5% CO2 
and subcultivated every 72 hours.  Vemurafenib was obtained from Selleck Chemicals 
(Houston, TX).  DMEM media (Invitrogen) was reconstituted in 500mL ultrapure H2O 
and supplemented with 20% FBS, 200 U/mL penicillin, and 200 μg/mL streptomycin for 
use in soft agar assays. 
Proliferation Assays 
Manufacturer protocols were followed to determine effect of lunasin on 
melanoma cell proliferation (Promega Cell titer-96 Aqueous Reagent).  Initial seeding 
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 in 100 μL culture media.  Briefly, cells 
were plated and incubated at 37˚C, 5% CO2 for 4 hours.  Media were drained from each 
well and replaced with media containing varying concentrations of lunasin.  Treatment 
media were replaced every 24 hours during the 72 hour treatment period.  After 72 hours 
of treatment, wells were drained of expired media and refilled with fresh media.   20 μL 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) reagent was added to each well and the plate was incubated for 2-3 
hours.  Absorbance was read at 490 nm on a plate reader (Biotek Instruments, Winooski, 
VT).  Average absorbance of media containing no cells was subtracted from all 
absorbance values.  Absorbance values were then normalized to control and expressed as 
percent control. 
Soft Agar Colony Forming Assay 
In order to assess the ability of lunasin to suppress anchorage-independent growth 
of cancer cell lines, cells were suspended in soft agar.  Solutions of 1% and 0.7% w/v 
Bacto Agar were mixed with equal volumes (1:1) of 2x DMEM media containing 20% 
FBS and 2% Pen-Strep.  2 mL of 0.5% agar solution was used to coat the bottom of each 
well in a 6-well plate and allowed to solidify in a laminar flow hood.  1x 10
3 
cells were 
suspended in a 1 mL top layer containing 0.3% agar with and without lunasin present and 
placed on top of the bottom layer of agar.  Plates were allowed to fully solidify and were 
placed in the incubator.  Generally, colony formation occurred within 2-3 weeks.  
Colonies were stained with a 1 mg/mL iodonitrotetrazolium chloride (Sigma-Aldrich, St. 
Louis, MO ) solution and counted using a light microscope. Images from each well were 
analyzed using ImageJ software (National Institutes of Health, Bethesda, Maryland). 
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ALDEFLUOR Staining and Flow Cytometry 
The ALDEFLUOR kit (Stem Cell Technologies, Vancouver, BC) was used to 
identify cells with high ALDH activity. Briefly, cells were suspended in assay buffer 
containing a fluorescent ALDH substrate and incubated for 30 min at 37 °C. The ALDH 
substrate passively diffuses into live cells and is then converted by ALDH into a 
fluorescent product detectible by FL-1 (FITC) signal.  A specific ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB) served as a negative control and allowed gating of 
ALDH-positive cells.  Becton, Dickinson, and Co. FACS Caliber (BD Biosciences San 
Jose, CA) was used for all flow cytometry experiments. 
Annexin V binding assays were conducted using FITC conjugated antibodies (BD 
Bioscience) and propidium iodide to measure rates of apoptosis/cell death.  Cells were 
harvested and resuspended in 1x binding buffer (0.1 M HEPES, pH 7.4; 1.4 M NaCl; 25 
mM CaCl2)  at a concentration of 1x10
6
 cells per mL.  Staining was conducted following 
manufacturer protocols.  Briefly, 1x10
5
 melanoma cells were incubated with 100 μM 
lunasin for 24, 48, and 72 hours.  Cells were suspended in 0.5 mL binding buffer and 
stained with 5 μL PI, 5 μL Annexin antibody, or both for 15 minutes at room 
temperature.  Gates were set based on controls (unstained, PI only, Annexin only).  1x10
4
 
events were collected per run. 
Cell cycle analysis was performed on synchronized melanoma cells; cells were 
serum starved for 72 hours and then released by addition of FBS during lunasin or 
vehicle treatment.  1x10
6
 cells were harvested and resuspended in 200 μL PBS.  Cells 
were slowly added to 4 mL ice cold 70% ethanol for overnight fixation at -20˚C.  After 
fixation, cells were spun down at 300g for 10 minutes and resuspended in 0.5 mL of PI 
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master mix (40 μg/mL PI, 100 μg/mL DNase in PBS) and incubated at 37˚C for 30 
minutes prior to flow anaylsis. 
Fluorescence-assisted Cell Sorting  
 A MoFlo cell sorter (Beckman Coulter, Brea, CA) was used for all 
fluorescence assisted cell sorting (FACS).  ALDH-positive and ALDH-negative fractions 
were isolated using FL1 signal and collected for subsequent in vitro and in vivo 
experiments.  Sorted cells were confirmed to be positively stained for ALDH by 
fluorescent microscopy under blue laser (illumination at 488 nm).   Because a relatively 
large population of melanoma cells expressed at least some basal level of ALDH, only 
ALDH-positive cells with high FL1 intensity were collected.  A representative histogram 
for FACS based on the ALDH biomarker is shown in Figure 3. 
Formation of Multicellular Oncospheres 
Stem-like cells isolated by FACS were cultured in low adherent T-25 flasks 
(Corning, Corning, NY) in DMEM culture media supplemented with 2% FBS at a 
density of 1x10
4
 cells/mL.  Cultures were grown for 28 days and treated every 48 hours 
during this time period with lunasin or vehicle in DMEM culture media.  Oncospheres 
began to form around 14 days and continued to grow until they were harvested, 
dissociated, and counted.  Visual counts of oncospheres were performed by light 
microscopy and analyzed using ImageJ software.  
In vivo Xenograft Model 
In vivo experiments using 6-8 week old, male athymic nude mice (Jackson labs 
Stock# 002019, Bar Harbor, Maine) illustrated the anticancer effects of lunasin in a 





cells reconstituted in 100 μL phosphate buffered saline (PBS) on the right flank.  
Intraperitoneal (IP) injections of 30 mg/kg lunasin reconstituted in 50 mM phosphate 
buffer, pH 7.4 (PB) were administered starting immediately after s.c. injection of tumor 
cells and repeated every 24 hours.  Noticeable tumor formation was observed 
approximately 14 days post-injection and measured every other day thereafter.  
Experimental endpoint was set at tumor volumes exceeding 20 mm in diameter or 
ulceration of tumor tissues.  At endpoint, mice were sacrificed and organs were resected 
for slide preparations.   




 cells were reconstituted in Hank’s Balanced 
Salt Solution (HBSS) +calcium +magnesium (Invitrogen) with an equal volume of 
Matrigel (BD Biosciences) and injected on the dorsal side of the mice at a total volume of 
100 μL.  Palpable tumor formation was observed at approximately 16 days post-injection 
and measured every other day as described above.  Again, organs were resected and 
blood was drawn via cardiac puncture upon sacrifice for future processing. 
SDS-PAGE and Immunoblot 
 Cultured cells were harvested by using enzyme free dissociation buffer to 
minimize protein degradation, spun down, and washed in ice-cold PBS.  After pelleting, 
cells were resuspended in appropriate amounts of RIPA buffer (250 mM Tris-HCl, pH 
7.5, 5 mM EDTA, 750 mM NaCl, 0.5% Lauryl sulfate, 2.5% Deoxycholic acid, 5% 
Igepal CA-630, Protease inhibitor cocktail containing 4-(2-aminoethyl) benzenesulfonyl 
fluoride (AEBSF), pepstatin A, bestatin, leupeptin, aprotinin and trans-epoxysuccinyl-L-
leucyl-amido(4-guanidino)-butane (E-64) (Sigma-Aldrich).  Protein concentrations of cell 
lysates were determined by a bicinchoninic acid (BCA) assay (Thermo Fisher Scientific, 
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Waltham, MA).  20 μg of protein were loaded into 10% polyacrilamide gels (BioRad, 
Hercules, CA) and run at 100 volts for 1 hour.  The protein was then transferred to a 
polyvinylidene difluoride (PVDF) membrane (BioRad) at 350 milliamps for 1 hour.  The 
PVDF membrane was blocked with 5% bovine serum albumin (BSA) or non-fat dry milk 
for 1 hour.  After several washing steps, primary antibodies were incubated with 
membrane at 4˚C overnight.  FAK (Cell Signaling, Danvers, Massachusetts), AKT (Cell 
Signaling), phospho-FAK (Cell Signaling), and phospho-AKT (Cell Signaling) 
monoclonal antibodies were diluted in Tris Buffered Saline with 0.1% Tween (TTBS) at 
1:1000 – 1:2000 v/v.  After three washes, secondary antibodies at 1:10,000 dilutions (Cell 
Signaling) were incubated with the membrane for 1 hour at room temp.  
Electrochemiluminescent (ECL) substrate/enhancer solutions (Thermo Fisher) were 
allowed to activate horseradish peroxidase (HRP) signal on membrane for 2-3 minutes; 
Chemiluminescence was developed on x-ray film and/or detected using a ChemiDoc 
station (BioRad). 
Non-steroidal anti-inflammatory drug (NSAID) Toxicological Panel and Complete Blood 
Count (CBC) 
 Whole blood was drawn from athymic nude mice by cardiac puncture 
immediately following CO2 asphyxiation and collected in serum separator tubes (BD 
Biosciences) or EDTA coated collection tubes (BD Biosciences).  25 μL of whole blood 
were collected in EDTA coated tubes and send to the RRC facility at the University of 
Louisville for CBC analysis.  After 1 hour post-collection, whole blood collected in 
serum separator tubes were centrifuged for 10 minutes at 10,000 g.  250 μL of serum was 
removed from each sample, collected in a 1.5 mL eppendorf tube, and send to the RRC 
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facility for NSAID toxicological analysis. Liver damage was assessed by levels of 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline 
phosphatase (ALKP).  Kidney damage was assessed by level of blood urea nitrogen 
(BUN) and creatinine (CREA). 
Statistical Analysis 
All data were analyzed in three independent experiments.  In vitro results were 
analyzed using GraphPad Prism (v 5.0) software and shown as mean ± standard deviation 
(SD).  Comparison of results from treated versus control cells was done using unpaired 
Student’s t test. A p-value of less than 0.05 was considered statistically significant.  In 
vivo experiments were statistically analyzed using GraphPad Prism ANOVA analysis tool 
(p<0.05), and shown as mean ± standard error (SEM).  Individual data points were 
compared by unpaired Student’s t test (p<0.05) to determine significance.  Interactions 
between lunasin and vemurafenib were determined to be antagonistic (< 1), additive (1), 
or synergistic (> 1) by calculating the Drewinko Index.  All samples were normalized to 
appropriate controls and applied to the formula DI = 
          
   
 in which SF
1
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Lunasin has modest antiproliferative effects on melanoma in adherent cell culture 
Proliferation assays remain an effective and high throughput method for screening 
drug efficacy.  We used a tetrazolium based proliferation assay to determine if lunasin 
displayed a significant antiproliferative effect on melanoma cell lines.  MTS results 
(Figure 4) indicate that lunasin marginally inhibits proliferation in adherent conditions 
and has an additive interaction with the B-Raf inhibitor vemurafenib as calculated by 
Drewinko Index assessment (DI = 1).  We replicated these experiments with cells isolated 
based on high expression of the ALDH biomarker using FACS.  ALDH positive cells 
showed no significant difference from the parental cell lines in terms of sensitivity to 
lunasin using this culture method.  Figure 4 illustrates that lunasin interacted additively 
with vemurafenib in both parental and ALDH
+ 
cells as assessed by DI. 
Lunasin reduced anchorage-independent growth of melanoma cells in soft agar 
Soft agar assays represent a robust system for screening cancer cells for drug 
sensitivity that is thought to be more representative of potential in vivo effects.  We 
observed a heightened sensitivity of melanoma cells to lunasin when plated in soft agar 
versus adherent culture conditions (Figure 5).  This is consistent with previous studies in 
our lab in which lunasin-insensitive NSCLC lines displayed lunasin sensitivity in a non-
adherent format (McConnell and Davis, unpublished data).  Lunasin showed a significant 
antiproliferative effect on A375 melanoma cells plated in soft agar.  30 μM lunasin 
reduced colony formation by approximately 25%, while 100 μM lunasin inhibited colony 
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formation by 38% (Figure 5A).  Along with decreased colony counts, a noticeable 
reduction in the size and change in phenotype accompanies lunasin treatment (Figure 5D) 
versus vehicle treated A375 cells (Figure 5E).  Cells treated with lunasin formed colonies 
that tended to be less dense and displayed a somewhat dissociated phenotype.   
Furthermore, we found that lunasin interacts additively with the specific B-Raf inhibitor 
vemurafenib.  A combination of 100 μM lunasin plus 300, 700, and 1000 nM 
vemurafenib yielded a significant decrease in colony formation, illustrating the potential 
application of lunasin as an adjuvant therapy in melanoma patients. 
Lunasin alone shows an antiproliferative effect on the SKMEL-28 melanoma cell 
line (Figure 5B).  Concentrations of 30 μM and 100 μM reduced colony formation of 
SKMEL-28 melanoma cells by 14% and 20%, respectively (Figure 5B).   The additive 
effect of lunasin was again measured with vemurafenib co-treatment; however, a 
statistically significant additive effect was not obtained at 700 nM vemurafenib.  
Anchorage independent growth is a hallmark of cancer; these data illustrate the utility of 
chemotherapeutics in disrupting proliferation of cancer cells in non-adherent conditions.  
From this, we concluded that concurrent treatment of lunasin and the B-Raf inhibitor 
vemurafenib could be a legitimate therapeutic strategy in malignant melanomas with the 
V600E mutation. 
Lunasin reduces the melanoma stem cell population in vitro 
We conducted initial experiments in which A375 and SKMEL-28cells were 
treated with 1 μM vemurafenib, 100 μM lunasin, and a combination of both agents.  
Melanoma stem cell markers (e.g. ALDH) in the cell population were analyzed by flow 
cytometry.  ALDH staining has been recognized as a technique to distinguish and isolate 
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melanoma stem cells from bulk tumor populations.  Our results indicated that both 
vemurafenib and lunasin are able to dramatically reduce the population of cells 
expressing measureable levels of ALDH (Figure 6).  This reduction in ALDH expression 
is time dependent.  An overall reduction in ALDH-positive cells was seen with lunasin 
treatment, vemurafenib treatment, and in combination treatment groups.   
Lunasin alone had a significant effect on ALDH expression in melanoma cells 
versus vehicle treatment (Figure 8).  ALDH positive populations were reduced by nearly 
50% in lunasin treated SKMEL-28 cells at 24 hours (Figure 8B).  This effect was seen at 
later time points, albeit, it was not significantly different from controls.  In A375 cells, 
ALDH positive populations were reduced by lunasin treatments; ALDH expressing cell 
populations were reduced 56%, 35%, 18%, and 22% for 24, 48, 72, and 96 hour time 
points, respectively (Figure 8A).  By effectively reducing the tumor initiating cells in 
culture, lunasin may inhibit primary tumor formation or alter metastatic growth by 
inducing terminal differentiation of cancer stem cells or by reducing CIC pools available 
to invade distant tissues. 
Cell cycling and apoptotic effects on melanoma 
Trypan blue exclusion tests were performed in concurrence with annexin binding 
assays to measure apoptotic rates within melanoma cell populations.  Initial experiments 
suggest that lunasin has little effect on cell viability; however, potentiates the apoptotic 
effects of vemurafenib in combination treatments (Figure 10).  At the later time points, it 
was clear that a number of cells in both A375 and SKMEL-28 treated samples were dead 
or dying; however, these observations were apparent in both control and lunasin treated 
samples.  Results from later annexin binding assays did not show a definitive increase in 
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early or late apoptotic populations within either cell line at 24, 48, or 72 hours in response 
to 100 μM lunasin (Figure 11).  Apoptotic and necrotic profiles for each treatment and 
time point were generated, but no significant difference was seen in either cell line; 
although, a clear trend in increasing early and late apoptotic cells was observed with 
lunasin treatment.  We therefore concluded that lunasin does not induce apoptosis or 
cause a necrotic response in the parental melanoma cell lines; however, we expect to 
isolate CICs based on the ALDH biomarker and determine if lunasin induces a selective 
apoptosis response in this subset of cells. 
Cell cycle analysis was performed using propidium iodide (PI) staining of DNA 
(Figure 9).  Briefly, cells were permeablized and fixed in 70% ethanol over night and 
resuspending in a PI master mix (PI 40 μg/mL, RNase 100 μg/mL in PBS).  Flow 
analysis commenced after a 30 minute incubation.  Interestingly, lunasin had little effect 
on cell cycling of either melanoma cell line before the 72 hour time point.  However, at 
72 hours, a decrease of cells in S-phase was seen.  These data may suggest lunasin has a 
delayed effect on cellular proliferation, and causes accumulation of cells in G0/G1 and 
G2 phases of the cell cycle.  Treatment with vemurafenib caused a decrease in S-phase 
throughout the time course, and an accumulation of cells in G0/G1 can be seen in both 
cell lines.  Combination treatment curves were similar to treatment with the B-Raf 
inhibitor, however, S-phase cycling was further reduced, and frequency of sub-G1/super-
G2 cells was modestly increased. 
Lunasin reduced phosphorylation of Akt and Fak in melanoma cells 
  Since lunasin was effective at inhibiting the growth of melanoma cells as colonies 
in soft agar, we studied whether it affects the signaling pathways associated with cell 
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growth and survival.  FAK and AKT are downstream mediators of integrin signaling.  
Figure 12 illustrates that total FAK (125 kDa) remains unchanged with lunasin treatment; 
however, tyrosine phosphorylation (Y397) is significantly impaired.  We next examined 
the serine phosphorylation (Ser473) of Akt (60 kDa), a downstream signal molecule of 
FAK.  As expected, the phosphorylation of Akt was observed in untreated cells and 
inhibited by treatment with lunasin.  These results confirm that downstream mediators of 
integrin signaling are severely affected by lunasin.  By effectively reducing active forms 
of Akt and Fak, signal transduction is interrupted, which may stimulate antiproliferative 
and antisurvival cell signaling.  Inhibiting these pathways may sensitize CICs with 
superior survival signaling and chemoresistance to traditional or targeted therapies (e.g. 
vemurafenib). 
In vitro effects of lunasin were potentiated in melanoma stem cells 
In order to determine whether or not lunasin has a selective apoptotic or 
antiproliferative effect on cancer stem cells, in vitro assays measuring proliferation and 
anchorage-dependent growth were performed, and the results from the ALDH-positive 
populations were compared to the parental lines.  Overall, lunasin had an increased effect 
in the ALDH
+
 sorted cells.  100 μM lunasin reduced colony forming ability in soft agar 
by approximately 40% and 75% in A375 and SKMEL-28 cell lines, respectively (Figure 
14A).  Interestingly, a reduction in colony size accompanied lunasin treatment in both 
cell lines versus vehicle treatment (Figure 14B-E) 
CICs have been reported to have enhanced ability to form oncospheres in low 
adherent conditions.  We assessed the ability of lunasin to disrupt formation of 
oncospheres derived from sorted samples based on the ALDH biomarker.  100 μM 
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lunasin almost completely inhibited spheroid formation in the A375 cell line versus 
control (Figure 13B and Figure 13C), while reducing spheroid counts and size in 
SKMEL-28 cells (Figure 13A).  When spheres were dissociated and counted, viability 
did not significantly change due to lunasin treatment; however, slightly reduced cell 
counts as determined by trypan blue exclusion assays were observed (data not shown).  
Furthermore, lunasin inhibited foci formation when A375 CICs were dissociated and 
replated at low density in adherent conditions (Figure 13D and Figure 13E).  ALDH 
positive cells quickly grew in tightly packed clusters of cells and formed foci within a 
matter of days.  Lunasin restores growth of these cells as a monolayer and inhibits foci 
formation in adherent culture.  These data suggest lunasin may convert the more 
tumorigenic ALDH expressing cells to the less aggressive phenotype of a terminally 
differentiated bulk tumor cell.  More research into possible mechanisms for this effect is 
warranted as little is known about the movement of melanoma cells in and out of the stem 
cell compartment.  Furthermore, a definitive link between cancer stem cells and integrin 
signaling has yet to be established in the roles of CSC differentiation, metastasis, and 
overall patient outcome. 
Lunasin had significant antimelanoma effects in vivo: 
Our results indicate lunasin substantially inhibits tumor formation and growth in 
an athymic nude mouse xenograft model.  30 mg/kg injections of lunasin reduced tumor 
volume by 35% and 55% with intravenous (Figure 15) and intraperitoneal (Figure 16) 
injections, respectively.  IV injections were administered every other day; IP every day.  
Tumor mass was also significantly decreased by lunasin treatments.  Upon necroscopy, 
whole tumors were resected and a wet tumor weigh was measured.  IP and IV lunasin 
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treatments resulted in a 46% and 34% decrease in wet tumor weights upon endpoint of 
the experiment.  These data delineate lunasin’s bioavailability and anticancer effects in an 
in vivo model.   
Non-steroidal Anti-inflammatory Drug (NSAID) toxicological panels showed 
lunasin treatments did not alter circulating plasma levels of liver enzymes ALKP, ALT, 
or AST.  These data suggest lunasin does not induce a toxicological response in mice and 
is safe for future therapeutic applications.  Furthermore, renal function was not impaired 
as measured by BUN and CREA.  Complete blood count (CBC) analysis revealed lunasin 
does not significantly alter levels of leukocytes, erythrocytes, or thrombocytes compared 
to control. 
Lunasin selectively inhibits MSC proliferation in vivo 
Male athymic nude mice (6-8 weeks old) were transplanted with 1x10
4
 cells that 
had previously been sorted using the ALDEFLUOR staining kit in an equal volume of 
HBSS (with calcium and magnesium) and Matrigel.  Tumor formation was established at 
16 days after injection and measured every other day thereafter.  Control vehicle and 30 
mg/kg lunasin were injected IP every 24 hours for the duration of the experiment.  Our 
results demonstrate the selective effect of lunasin on melanoma stem cells expressing the 
ALDH biomarker.  These cells are generally accepted to have enhanced tumorigenic 
capacity versus non-sorted bulk tumor cells.  Compared to our previous study in which 
we injected 2.5x 10
6
 bulk A375 cells, MSCs displayed superior tumor forming ability. 
MMICs established palpable tumors in a similar amount of time compared to 
parental tumor cells, however, this experiment utilized Matrigel in order to keep MMICs 
localized to subcutaneous tumor growth.  Matrigel contains growth factors which may 
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boost cell proliferation; therefore, we concede that our MMIC and parental models are 
not comparable in terms of tumor growth rates.  Lunasin did not decrease the number of 
tumors formed, but reduced tumor burden by 74%, a nearly 50% increased effect versus 
parental A375 cells.  Onset of tumor formation was delayed in lunasin treated mice; 
tumors also displayed linear growth versus the exponential growth seen in control mice.  
Wet tumor weights for lunasin treated mice were reduced by 66%, thus illustrating the 





Lunasin has previously been shown to have chemotherapeutic effects in a number 
of cancer models [3, 23, 25, 83-85].  To our knowledge, this is the first study identifying 
the anticancer effects of lunasin in a melanoma model.  Therapies for treating patients 
with malignant melanoma remain largely ineffective, despite novel targeted therapies that 
show clinical improvements over traditional alkylating agents.  Here we show that 
lunasin has potential clinical utility as both an adjuvant therapy as well as a standalone 
chemotherapeutic against malignant metastatic melanoma.  Our data suggest that lunasin 
interacts with subsets of integrin subunits and interrupts internal signaling cascades 
induced by integrin activity. 
Although HAT inhibition is generally regarded as the prime mechanism for 
lunasin’s chemotherapeutic and chemopreventive attributes, we suggest the interactions 
between the RGD-peptide and integrin dimers found on the cell surface to be essential 
mechanisms in the in vitro and in vivo effects found in this study.  Utilizing proximity 
ligation assays, we have shown that lunasin interacts with specific integrins (Ianaba and 
Davis, unpublished data), evidence supported by recent studies on integrin mediated 
endocytosis [27].   
We do not postulate that the described effects are due to the epigenetic effects 
stimulated by lunasin treatment; though, we have found that lunasin does indeed affect 
patterns of histone acetylation in melanoma cells in vitro (data not shown).  Because 
integrins are explicitly involved in cell adhesion and division, we concluded that 
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reductions in clonogenic capacity in soft agar and formation of multicellular oncospheres 
in low adherent culture are attributed to the disruption of adhesive signaling mediated by 
integrins.  We agree that HAT inhibition does have global cellular effects; however, we 
believe that lunasin binding of integrins through its RGD domain is responsible for 
lunasin’s anticancer activity in our melanoma models.  However, in vivo effects may 
stem from a variety of cellular effects induced by lunasin including integrin antagonism, 
epigenetic modifications, and immunomodulatory functions. 
Integrin signaling can regulate the stem cell processes of self-renewal, 
differentiation, and proliferation [86].  We have shown that lunasin treatment altered 
these processes and diminished intracellular interactions with Akt and Fak in vitro and 
resulted in decreased tumor burden in vivo.  Though lunasin decreased tumor burden in 
mice injected with parental A375 melanoma cells, these effects were exacerbated in 
MMIC populations in our xenograft models.  Furthermore, we confirmed that lunasin 
depleted the stem cell pool by reducing ALDH signal in established melanoma cell lines.  
These effects may be associated with the ability of lunasin to induce terminal 
differentiation of CICs or by altering downstream mediators of integrin signaling.  The 
enhanced effects seen in MMIC populations suggests that cancer stem cells may rely on 
integrin signaling for proliferation and differentiation, more so than bulk tumor 
populations.  These finding are consistent with recent studies that suggest FAK as well as 
β1 integrin subunits regulate stem cell pools in breast cancer [87]. 
Fak normally functions as a scaffolding protein to mediate signal transduction, 
however, Fak also serves as a non-receptor tyrosine kinase mediating signal transduction 
from external stimuli.  Several studies correlate Fak overexpression or amplification with 
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advanced disease resulting in poor prognosis [88, 89], consequently, targeting of FAK 
may provide a novel therapeutic strategy for inhibiting metastatic disease progression.  
FAK has been shown to arbitrate stem cell maintenance and differentiation in cancer 
models [50, 51].  FAK association and activation of PI3K leads to increased production 
of phospholipids, which can in turn activate Akt kinase [90, 91].  Again, these finding are 
consistent with the results in our melanoma model as lunasin decreased phosphorylation 
of Akt.  Therefore, integrin signaling through FAK may play an essential role in 
melanomagenesis or disease progression and metastasis; a pathway targeted by the 
lunasin peptide. 
Crosstalk between PI3K/Akt and NOTCH signaling pathways in melanoma has 
been well documented [92, 93].  NOTCH signaling has been implicated in stem cell 
processes such as self-renewal, differentiation, survival, and proliferation [94, 95].  It is 
plausible that the decreased Akt phosphorylation seen in melanoma cells is mediated 
through NOTCH signaling.  Further studies are necessary to clarify whether or not 
lunasin induces changes in the PI3K/Akt pathway through NOTCH family receptors. 
Another aspect of melanoma development is the theory of direct phenotype 
switching [96, 97].  To summarize, three distinct compartments exist in cancers; a highly 
proliferative cell with low invasive capability, a differentiated phenotype derived from 
daughter cells of divided stem-like cells, and an invasive, stem-like, quiescent phenotype 
that regenerates stem cell pools.  Switching between these subsets may rely on certain 
genes such as microphthalmia-associated transcription factor (Mitf) and NOTCH.  
NOTCH activity is frequently elevated in melanomas; it also maintains melanoctye stem 
cell populations [98].  As discussed previously, NOTCH can mediate PI3K/Akt 
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signaling; overexpression of AKT by NOTCH1 provides a key step in promoting an 
invasive phenotype [99].  It has been shown that NOTCH1 is able to hyperactivate 
PI3K/Akt signaling through NF-ĸB [93], a pathway previously revealed to be inhibited in 
human macrophages by lunasin treatment [2]. 
Mitf has been established as a differentiation marker in melanocytes; however, 
Mitf has also been reported to mediate proliferation, differentiation, and plasticity of 
melanoma cells [100].  Insightful studies have addressed that melanomas with a negative 
Mitf phenotype are generally quiescent, yet highly invasive [101].  Inversely, melanoma 
cells highly expressing MITF proliferate rapidly, but do not seem to metastasize.  In 
support of these findings, inhibition of MITF increased expression of stem cell markers 
Nanog and Oct4 resulting in enhanced tumor growth in C57/B6 mice [102].  Again, 
culture conditions played a major role in expression of differentiation and stem markers 
[100, 103].   Hoek and Goding summarize: “If the combination favours the proliferative 
phenotype over the invasive, a tumour may grow rapidly, but for a given size, it will seed 
fewer metastases than a tumour whose cells are not subject to a proliferative phenotype 
bias.” [97]  This hypothesis highlights the potential of selectively targeting cancer stem 
cells instead of relying on drugs targeting rapidly dividing cell populations to increase the 
overall efficacy of treatment in metastatic melanomas. 
Clearly, these signaling pathways are implicated in both physiological and cancer 
stem cell processes.  Our results show an apparent decline in cancer stem cell pools that 
may be influenced by these pathways; however, the potentiated effect in ALDH positive 
MSCs cannot be fully explained until further research elucidates lunasin’s effects on 
certain genes and gene products responsible for maintenance, proliferation, and 
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differentiation of stem-like cancer cells.  Our data hints that lunasin may alter stem pool 
maintenance and proliferation, and therefore, has clinical utility in cases of late stage 
melanoma in which traditional therapies have failed.  Future studies in our lab will focus 
on exploring the alterations induced by lunasin on cancer stem cell populations in 






SUMMARY AND CONCLUSIONS 
The soy-derived peptide lunasin has significant activity as a chemopreventive [7]; 
however, lunasin also serves as an anticancer agent in established cancer models [24, 83].  
Lunasin treatment reduces the capacity of melanoma cells to form oncospheres in low 
adherent culture as well as inhibits clonal growth in soft agar.  We believe these results 
stem from an interaction between lunasin and integrins on the ECM through its RGD 
domain, and results in decreased phosphorylation of intracellular signaling proteins such 
as Fak and Akt.  In vivo studies show lunasin significantly decreased tumor growth in 
athymic nude mice injected subcutaneously with A375 melanoma cells.  Tumor volume 
and weight were reduced by 55% and 46%, respectively.  These data illustrate the 
potential clinical utility of lunasin against malignant melanoma. 
Furthermore, we present a unique study showing the enhanced effects of lunasin 
against stem-like melanoma cells which display superior tumor forming capability 
compared to bulk tumor cells.  Using ALDH, a recognized MMIC biomarker [77], we 
isolated cells expressing distinctively higher levels of the enzyme and subjected them to 
further in vitro testing.  We found that MMIC response to lunasin treatment was 
potentiated versus the parental cell lines both in vitro and in vivo.  30 mg/kg lunasin 
treatment reduced tumor burden in our melanoma xenograft model by approximately 
75%.  Despite using appreciably fewer cells to initiate tumor formation, ALDH 
expressing cells formed palpable tumors within a comparable amount of time versus bulk 
tumor populations.   
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The functional assays in this study illustrate the prospective use of lunasin as a 
chemotherapeutic against melanomas in which traditional therapy has failed.  
Additionally, we showed that extended lunasin treatment displayed no toxicological 
effects versus control in our animal model.  However, we have only begun to elucidate 
mechanisms in which lunasin acts as an anticancer agent.  While epigenetic effects 
undoubtedly play a major role in tumorigenesis, we feel that lunasin has several critical 
effects on integrin signaling and further, CIC maintenance and proliferation resulting in 
the augmented effects seen in MMICs. 
It must be taken into consideration that several theories exist in which cells are 
able to move between stem and differentiated cell compartments; theories in which 
melanoma serves as a prime example.  If this is the case, more research is warranted to 
determine if A) lunasin is inducing terminal differentiation of melanoma cells, B) 
confirm ALDH as a viable biomarkers for MMIC populations by utilizing alternative 
markers, and C) analyze the alterations in gene expression patterns induced by lunasin 





Figure 1: Lunasin represses transcription of target genes by inhibiting HAT binding to histone 
tails.  It is proposed that lunasin binding causes hypoacetylation of chromatin leading to cell 








Figure 2: Integrin signaling mediated by FAK and ILK can lead to abundant cellular effects including 











 Figure 3: FACS based on the ALDH biomarker resulted in ~20% of the 
A375 melanoma cell population staining positive.  DEAB served as a 
negative control by inhibiting ALDH cleavage of the fluorescent 





Figure 4: Tetrazolium-based proliferation assays (i.e. MTT) showed A375 and SKMEL-28 
melanoma cell lines are relatively insensitive to lunasin (100 μM) treatment in adherent conditions.  
ALDH-positive cells showed little sensitivity in this format as well, however, lunasin still interacted 

















Figure 5: Lunasin and vemurafenib combination treatments show the potential of lunasin as an 
adjuvant treatment of (A) A375 and (B) SKMEL-28 melanoma cells by reducing colony forming 
ability in soft agar. (C) 100 μM lunasin (bottom well) reduced colony formation by approximately 
40% and 20% in A375 and SKMEL-28 melanoma cell, respectively.  (D)  Control A375 colonies 
formed tight, well defined colonies in soft agar that were larger than (E) lunasin treated colonies. 





BRAF (1 M) BRAF + Lunasin 
Cell Line A375 SKMEL-28
ALDH Intracellular staining for CIC's
Control 34.50% 32.80%
24HRS 100uM Lunasin 20.60% 17.80%
1uM Vemurafenib 6.61% 16.30%
Lunasin + Vemurafenib 4.60% 9.02%
Control 53.50% 55.00%
48HRS 100uM Lunasin 41.40% 48.60%
1uM Vemurafenib 5.20% 41.20%
Lunasin + Vemurafenib 3.19% 47.50%
Control 40.40% 49.80%
72HRS 100uM Lunasin 31.00% 27.80%
1uM Vemurafenib 18.50% 0.10%
Lunasin + Vemurafenib 8.35% 0.05%
ALDH ControlDEAB
 
Figure 6: Lunasin and vemurafenib treatment decreased the number of ALDH
high
 cell populations  in 
A375 and SKMEL-28 melanoma cells.  Combination treatment further reduced ALDH expression in 





















Figure 7: ALDH represents a unique biomarker to identify and isolate melanoma stem cells.  
Here we use the specific ALDH inhibitor DEAB as a negative control (A) to determine 
parameters for ALDH-positive (B) cells.  We show that 100 μM lunasin (C) treatments for 24 
hours reduced ALDH expressing populations in melanoma cell lines, while concurrently 






Figure 8: ALDH expression was significantly reduced by 100 μM lunasin 
treatments (A) lunasin reduced ALDH expressing cell populations by 56%, 35%, 
18%, and 22% for 24, 48, 72, and 96 hour timepoints, respectively.  (B) ALDH 
expressing cell populations were significantly reduced at 24 hours in SKMEL28 
melanoma cells, but only marginally at later time points. Statistical significance 








BRAF + Lunasin 
Figure 9: Cell cycle analysis by PI stain.  Lunasin had little effect on cell cycling at early time points, 
but caused a significant drop in cells in S-phase after 72 hours for the A375 cell line.  Vemurafenib 
inhibited cell cycling throughout the experiment; this effect was enhanced with lunasin co-treatment. 
(n=1) 
A375 SKMEL-28
G1 S G2 Sub-G1 Super-G2 G1 S G2 Sub-G1 Super-G2
Control 20.06 36.71 25.79 2.86 8.97 52.5 36.85 8.18 0 0
100uM Lunasin 22.03 35.39 24.99 2.25 8.84 41.24 35.61 9.49 1.58 3.95
1uM Vemurafenib 28.26 22.86 29.22 2.79 13.88 64.99 15.18 4.75 8.84 6.24
Lunasin + Vemurafenib 25.43 21.04 29 3.21 17.23 44.83 15.6 39.44 8.52 24.83
Control 40.8 32.6 29.6 1.31 3.19 53.7 26.2 8.1 0.74 0.73
100uM Lunasin 38.5 32.8 20.1 2.16 3.09 51.9 25.6 11.9 1.56 0.36
1uM Vemurafenib 77.4 14.2 3.6 2.22 0.04 72.7 15.7 2.8 4.79 1.27
Lunasin + Vemurafenib 70.3 13.1 9.6 2.62 3.73 63.7 18.2 4.6 6.64 3.04
Control 42.2 36.5 14.3 4.81 2.2 45 21.8 6.1 4.71 0.06
100uM Lunasin 37.3 8.1 22.7 4.27 24.2 36.6 18.9 8.7 2.34 4.24
1uM Vemurafenib 38 6.6 20.8 9.99 22.23 69.2 7.4 0.5 13.73 0.03




Control Lunasin (100 M)
BRAF + Lunasin BRAF (1 M)
A375 SKMEL-28
QI QII QIII QIV QI QII QIII QIV
Annexin V Binding
Control 3.24 2.33 94.1 0.284 8.82 7.42 80.5 3.22
100uM Lunasin 4.53 3.82 91.1 0.565 7.89 6.78 81.6 3.77
1uM Vemurafenib 5.69 3.87 89.7 0.729 6.11 6.2 81.3 6.39
Lunasin + Vemurafenib 7.71 3.86 87.9 0.571 9.21 4.79 80.1 5.89
Control 6.19 6.71 86 1.11 22.8 11.5 64.2 1.59
100uM Lunasin 3.14 9.22 84.2 3.43 25.2 11.1 62.3 1.32
1uM Vemurafenib 6.13 11.5 75.9 6.48 30.5 8.15 60.3 1.08
Lunasin + Vemurafenib 6.97 13.9 72.2 6.92 40.1 8.39 49.8 1.66
Control 8.39 11.2 79.5 0.861 16.7 9.96 72.7 0.678
100uM Lunasin 14.4 6.41 78.8 0.353 19.5 16.7 63.4 0.396
1uM Vemurafenib 15.1 12.4 72.3 0.273 24.5 16.9 57.8 0.804
Lunasin + Vemurafenib 18.2 13 68.5 0.223 35 12.9 51.6 0.619
 
Figure 10: Annexin V binding assays were used to assess apoptotic profiles for A375 and SKMEL-28 
melanoma cell lines in response to vemurafenib and lunasin treatments.  Lunasin again potentiated the 
effects of vemurafenib in both cell lines resulting in decreased viability and a concomitant increase in 







Figure 11: Apoptotic profiles were generated using the Annexin V binding assay.  A375 cells treated 
with 100 μM lunasin did not have a significant number of apoptotic cells versus vehicle treated cells 
until 72 hours.  Although significance was not evident, a trend of decreased viability due to lunasin 















 Figure 12: Immunoblot analysis of 20ug total protein from A375 
cell lysates.  Lunasin treatment decreased phosphorylation of (B) 
Fak and (D) Akt.  Unphosphorylated protein content of (A) Fak and 
(C) Akt remain stable in all samples.  (E) Actin was used as a 








Figure 13: 100 μM lunasin reduced formation of oncospheres in A375 and 
SKMEL28 cell lines. (A) lunasin inhibited melanoma stem cells from forming 
oncospheres in low adherent culture.  (B) Control wells contained A375 spheroids 
cultured for 28 days  (C) lunasin treatment inhibited A375 oncosphere formation in 
low adherent culture  (D) A375 ALDH+ MSCs were replated into adherent T-25 
flasks and allowed to form foci on the plate  (E) lunasin treatment completely 
inhibited foci formation. Significance is denoted by asterisk as assessed by Student’s 







Figure 14: Colony formation in soft agar was significantly reduced with 
100 μM lunasin treatment. (A) Colony formation in soft agar was 
significantly reduced in both A375 and SKMEL-28 cell lines.  Cell 
proliferation was reduced as been by the smaller colony size in lunasin 
treated A375 (B) and SKMEL-28 (D) cell lines versus phosphate buffer 
controls (C,E). Significance is denoted by an asterisk and assessed by 
Student’s T test (p < 0.05). 
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Figure 15: A375 cells formed subcutaneous tumors in nude mice. IV injection of 
30 mg/kg lunasin in athymic nude mice resulted in a 34% decrease in tumor 
volume (A) and 35% decrease in tumor weight versus (B) phosphate buffer treated 
control mice. Statistical significance was determined by ANOVA (p < 0.05) using 






Figure 16: In-vivo xenograft models utilizing athymic nude mice illustrate the potential 
therapeutic advantage to the soy-derived peptide lunasin. (A) Wet tumor weight from resect 
tumor tissues.  30 mg/kg lunasin treatment reduced tumor weights by 46%. (B) Tumor volume 
was reduced by 55% and represented a significant difference from phosphate buffer control as 









Figure 17: Lunasin showed no apparent liver (A) or kidney (B) damage as assessed by NSAID 
toxicological panels.  Complete blood counts (C,D,E) also illustrate the safety of continual 





Figure 18: Melanoma stem cell xenograft model (A) 30 mg/kg lunasin treatment reduced tumor 
weight by 64% compared to phosphate buffer control. (B) Tumor volume was also significantly 
reduced 74% versus control vehicle. Statistical significance was determined by ANOVA (p < 
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